Two serial MoCA assessments may support biomarker-sparing triage between Parkinson’s disease/Lewy body dementia and frontotemporal dementia: a progressive inclusion analysis of 1,129 participants
Reliable differentiation of Parkinson’s disease/Lewy body dementia (PD/LBD) from frontotemporal dementia (FTD) affects treatment strategy and clinical trial eligibility, yet confirmatory biomarker testing remains costly and unevenly available. Whether routine cognitive trajectories can support testing prioritization ha...